Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...
Johnson & Johnson (NYSE: JNJ) traded lower on Wednesday after the MedTech giant disclosed a temporary pause in U.S. cases treated with its Varipulse Pulsed Field Ablation Platform, which targets ...
“out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. Varipulse cases while it investigates the cause of four reported ...
Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ('Johnson & Johnson') (NYSE:JNJ) concerning ...
Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External ...
Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...
Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...
Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External ...
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
RYBREVANT and LAZCLUZE in lung cancer and VARIPULSE and the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter in electrophysiology. In closing, I want to thank everyone at Johnson & Johnson for all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback